Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Hvilsted Rasmussen

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Ugeskrift for Laeger|September 11, 2009
[Endoscopy in patients receiving anticoagulation therapy I]Lars Hvilsted Rasmussen, Steen Husted
Thrombosis and Haemostasis|July 12, 2012
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillationFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen
Journal of the American College of Cardiology|May 12, 2012
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillationGregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Thrombosis Research|January 22, 2014
Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort studyPeter Brønnum Nielsen, Søren Lundbye-Christensen, Lars Hvilsted Rasmussen, et al.
Journal of the American College of Cardiology|January 1, 2013
Reply: To PMID 22575324Gregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Thrombosis and Haemostasis|March 1, 2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysisFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, et al.
Journal of the American College of Cardiology|March 16, 2015
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc scoreGregory Y H Lip, Flemming Skjøth, Lars Hvilsted Rasmussen, et al.
Stroke|March 29, 2014
Age dependence of risk factors for stroke and death in young patients with atrial fibrillation: a nationwide studyLine Melgaard, Lars Hvilsted Rasmussen, Flemming Skjøth, et al.
BMJ Open|November 16, 2014
Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: a population-based cohort studyJacob Gamst, Christian Fynbo Christiansen, Bodil Steen Rasmussen, et al.
Critical Care (London, England)|August 20, 2015
Pre-existing atrial fibrillation and risk of arterial thromboembolism and death in intensive care unit patients: a population-based cohort studyJacob Gamst, Christian Fynbo Christiansen, Bodil Steen Rasmussen, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Ugeskrift for Laeger|September 11, 2009
[Endoscopy in patients receiving anticoagulation therapy I]Lars Hvilsted Rasmussen, Steen Husted
Thrombosis and Haemostasis|July 12, 2012
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillationFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen
Journal of the American College of Cardiology|May 12, 2012
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillationGregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Thrombosis Research|January 22, 2014
Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort studyPeter Brønnum Nielsen, Søren Lundbye-Christensen, Lars Hvilsted Rasmussen, et al.
Journal of the American College of Cardiology|January 1, 2013
Reply: To PMID 22575324Gregory Y H Lip, Torben Bjerregaard Larsen, Flemming Skjøth, et al.
Thrombosis and Haemostasis|March 1, 2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysisFlemming Skjøth, Torben Bjerregaard Larsen, Lars Hvilsted Rasmussen, et al.
Journal of the American College of Cardiology|March 16, 2015
Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc scoreGregory Y H Lip, Flemming Skjøth, Lars Hvilsted Rasmussen, et al.
Stroke|March 29, 2014
Age dependence of risk factors for stroke and death in young patients with atrial fibrillation: a nationwide studyLine Melgaard, Lars Hvilsted Rasmussen, Flemming Skjøth, et al.
BMJ Open|November 16, 2014
Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: a population-based cohort studyJacob Gamst, Christian Fynbo Christiansen, Bodil Steen Rasmussen, et al.
Critical Care (London, England)|August 20, 2015
Pre-existing atrial fibrillation and risk of arterial thromboembolism and death in intensive care unit patients: a population-based cohort studyJacob Gamst, Christian Fynbo Christiansen, Bodil Steen Rasmussen, et al.
Pageof 7